We’re not going to comment on our partners, which obviously will have their own news flow. So beyond the Vudalimab and 564, those are the things to watch for, and we’ll give specific guidance as we get a little closer to the dates.
Brian Chang: That’s helpful. Thank you.
Operator: Thank you. One moment for our next question. Our next question comes from the line of Alec Stranahan from Bank of America. Your line is open.
Alec Stranahan: Great. Hey, thanks guys. Thanks for taking my questions. Just a couple from us. The first is on the lung cancer study for vudalimab. Any additional thoughts around not including Vudalimab monotherapy cohort in the study? Is this driven more by the standard of care in non-small cell lung? Or is there something from the prostate study that you’re seeing that’s driving this? And then second question is just on expectations around partnership revenues, specifically, any color around what you expect from setrusumab from hear this year given that it was a pretty big contributor last year. Thank you.
Bassil Dahiyat: I’ll take the setrusumab question. We expect none. We reported almost none in the second quarter. Yeah. So we expect strived to be done. Maybe on the lung cancer and why not monotherapy, Nancy can go through the rationale there?
Nancy Valente: Yeah. Most of lung cancer are nonsquamous non-small cell is treated with chemotherapy, even patients, it turns out that should be eligible for just checkpoint inhibitor alone. And so we decided we’d go there. We’re going to look at PD-L1 expression or TPS less than 50%, 49% and lower. So that’s also specifically the chemotherapy part of the non-small cell lung cancer world, like that’s definitely where it’s used. So those are the reasons.
Alec Stranahan: Thank you.
Operator: Thank you. Please standby for our next question. The next question comes from Kaveri Pohlman of BTIG. Your line is open.
Kaveri Pohlman: Good afternoon. And thanks for taking my questions. For 819, I just want to know what makes kidney cancer attractive for this molecule. I know you mentioned ENPP3 has a strong expression, but do you expect T cells to work fairly well after first-line checkpoint inhibitors? And are there any other tumor types where you see opportunities?
Bassil Dahiyat: Yeah. I think I’ll let John Desjarlais, our CSO, take that question. He’s expert in all things the ENPP3.
John Desjarlais: Yeah. Thanks for the question. So I guess maybe the better way to think about it is we like ENPP3 because we’re basically first-in-class for CD3 bysacivic. It is very strongly and essentially uniformly expressed in clear cell renal cell carcinoma. And there’s a few other histologies where there could be high ENPP3 expression, but we wanted to prioritize for renal cell, mostly just to develop a signal once we establish that, then sure with perhaps a companion diagnostic, we could expand into a few other tumor types.
Bassil Dahiyat: And John, maybe the question.
Charles Liles: The other aspect of your questions yeah, with T-cell. Yeah, it’s interesting you asked that it turns out that kidney cancer, if you look at RNA expression levels for T-cell markers, it’s actually one of the highest histologies for having a T-cell presence, kind of consistent with the immune checkpoint inhibitors being very active in renal cell carcinoma. And we don’t think there’s any scientific reason why progression on a checkpoint inhibitor would have much impact on the future effects of it [ph]?
Kaveri Pohlman: Got it. That’s very helpful. Thank you. And maybe one on plamotamab. So you selected a step of dosing to manage CRS. But can you tell us about the safety profile? Do you think with this step-up schedule, you can avoid hospitalization requirement that other bispecifics have?
Bassil Dahiyat: So we’ll address that in the context of the formulation moving forward, our subcu in collaboration with Janssen, which does limit somewhat how much detail we can give. But I mean, I don’t know, Nancy, do you want to take that? Or that’s a goal. I don’t know that we have enough data to say yet.
Nancy Valente: Yeah. Certainly, that’ll be a goal. I think there’s some bispecifics that require a lot of hospitalizations, some that are minimal. Our goal would be to go for the minimal amount that’s appropriate as we look at the safety. And then it’s really about optimizing the step doses to make sure that you have CRS, the patient is primed and not having too much CRS such that it’s dangerous and requires hospitalization or. Yeah. But — so definitely, that’s our goal. And I think a product like Plamo given subcu could probably reach that like having less hospitalizations.
